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1. Introduction
Sidney Ringer, in 1882, was the first to recognize
the relevance of calcium, an element discovered in
w x1908 1 , for cellular function. He discovered the
necessity of Ca2q for heart contraction and described
its role during development of fertilized eggs and cell
w xadhesion 2–4 . In the late 1920s, it became evident
that intracellular Ca2q is the link between hormone-
receptor binding and cellular responses like secretion
w xor movement 5–8 . Understanding the biological
role of Ca2q depended on methodological progress.
First intracellular measurements of free Ca2q using
w xmicroinjection and the dye alizarin sulphonate 9
were controversial. An important breakthrough was
the introduction of the Ca2q-sensitive photoprotein
w xaequorin by Ridgway and Ashley 10 , and further
improvements by metallochromic Ca2q indicators
w x11 . The still rather limited sensitivity was overcome
2q w x 2qby Ca microelectrodes 12 and by Ca -sensitive
w xfluorescent dyes, like indo-1 and fura-2 13,14 .
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The clinical interest in Ca2q was initially limited.
It focused on changes in serum Ca2q since hypocal-
w xcemia resulted in tetanic muscle spasms 15 . Later
the hormonal regulation of serum Ca2q level was
investigated. The development of organic Ca2q chan-
nel blockers created pharmacological tools which
replaced the therapeutic regimens of many diseases,
w xfor example hypertension and arrhythmias 16,17 .
Fleckenstein was the first to correlate the negative
inotropic effect of Ca2q antagonists to an inhibition
of excitation–contraction coupling via a reduced Ca2q
w xentry 18 . This observation implied also a pivotal
role of intracellular Ca2q in pathophysiological situa-
tions.
2q w 2qx .To date, cytosolic Ca concentration Ca i
has been involved in numerous important cellular
w xfunctions, like growth and cell division 19–21 , ex-
w x w xcitability 22 , contraction 23 , volume regulation
w x w x24,25 , and exocytosis 26 . Resting levels of around
100 nM, some 10,000-fold below extracellular Ca2q
are generally observed. This disequilibrium is the
result of a limited Ca2q permeability of the plasma
membrane, active Ca2q extrusion processes and
2q w xintracellular Ca buffers 27 . Certain physical, elec-
trical, or chemical stimuli evoke a Ca2q response
w 2qxwhereby levels of Ca of around 1 mM arei
reached. Calcium might exert its effect directly, via
activation of certain ion channels, or indirectly via
w xactivation of additional mediators 28 .
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This review will first summarize Ca2q-transporting
systems, intracellular Ca2q buffers, and their integra-
tion under basal and stimulated conditions. Next,
examples of disturbed Ca2q homeostasis and of im-
paired Ca2q signalling under pathophysiological con-
ditions in various tissues are discussed. Finally, a
pathophysiological concept is presented. The authors
decided not to include the detailed role of Ca2q in the
programmed cell death, apoptosis, since this would
exceed the scope of this review. For this topic the
w xreader is referred to other publications 29–31 . Fur-
thermore, specific problems related to transepithelial
calcium transport were also not covered; they have
w xbeen reviewed recently by several authors 32,33 .
2. Cellular calcium homeostasis
w 2qx 2qCa is a balance between Ca -increasing,i
Ca2q-decreasing, and Ca2q-buffering mechanisms
 .Fig. 1 . Although in the following these processes
are presented separately, they are act hand-in-hand in
w 2qxadjusting Ca to the appropriate level.i
2.1. Calcium increasing mechanisms
In addition to the Ca2q gradient across the plasma
membrane there exist Ca2q concentration differences
Fig. 1. Schematic diagram of cellular Ca2q homoeostasis. Intra-
cellular Ca2q concentration is a result of the interplay of Ca2q-
increasing, Ca2q-decreasing, and Ca2q-buffering mechanisms.
BP s binding protein, M s mitochondria, ER s endoplasmic
reticulum, SRssarcoplasmic reticulum, SERCA sCa2q-ATPase
in SR and ER, PMCA sCa2q-ATPase in the plasma membrane.
within the cell, since Ca2q is sequestered in intra-
w 2qxcellular stores. Ca can be increased by two ways:i
release from internal stores or influx from the extra-
cellular space. In both cases Ca2q moves passively
along its electrochemical gradient.
2.1.1. Intracellular calcium stores
2q w xCa is stored in multiple ways 34 . Intracellular
deposits of Ca2q salt crystals are seen under patho-
logical conditions, e.g., in atherosclerosis, pancreatic
w xnecrosis, nephrocalcinosis, etc. 35 . In vertebrate
cells Ca2q is usually stored as free or bound Ca2q in
intracellular pools with exchange rates that range
from seconds to hours or days. Little is known about
the slowly exchanging Ca2q pools; these stores are
most likely localized in mitochondria or acidic com-
partments like endosomes, lysosomes and the trans
w xGolgi network 36 .
Rapidly exchanging Ca2q stores have been de-
scribed in the microsomal fraction, that mainly con-
 .sists of endoplasmic reticulum ER , which could be
 .stimulated by inositol-1,4,5-trisphosphate IP to re-3
2q w xlease Ca 34,37,38 . Using immunogold-labeling
techniques, Ca2q release channels and Ca2q transport
w xproteins have been detected close to the ER 39 .
Thereby, the ER and its analog in muscle cells, the
 .sarcoplasmic reticulum SR , have been identified in
2q w xmost cells as the main Ca pools 40 . There seem
to be regional differences in Ca2q storage properties
of the ER, in some cells, specialized subcompart-
w xments, called calciosomes exist 41 . In chromaffin
cells different spatial Ca2q signals correlated to dif-
ferent localization of Ca2q-ATPase-like proteins have
w xbeen observed 42 . Furthermore, a nonhomogeneous
distribution of IP and ryanodine channels, of sarco-3
 .plasmic reticulum calcium pumps SERCAs , and of
the Ca2q binding protein calsequestrin has been
shown, suggesting different regions for Ca2q uptake
2q w xand Ca release 42,43 . In cells possessing both IP3
and ryanodine-sensitive Ca2q channels a Ca2q re-
lease after IP stimulation does not prevent a further3
release via stimulation of the ryanodine receptor and
vice versa. Pools of a different IP sensitivity or of a3
w xdifferent IP receptor density seem to exist 44,45 .3
GTP and the cytoskeleton appear to organize and
2q w xconnect different IP -sensitive Ca pools 46 . There3
exist further cell-type specific storage pattern in addi-
2q wtion to IP and ryanodine-sensitive Ca pools 47–3
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x51 , enabling various cells to respond to physiological
w xstimuli in an individual way 44 .
The Ca2q storage capacity of SR or ER critically
depends on the intraluminal Ca2q binding proteins
w xcalsequestrin and calreticulin 52 . Calsequestrin is
the main intraluminal component of SR in skeletal
w xand cardiac muscle 53,54 , whereas calreticulin oc-
curs mainly in smooth muscle SR and non-muscle
w xER 55,56 . Their intraluminal distribution varies from
w x 2qhighly focused to homogeneous 57 . Both Ca
 .binding proteins CaP have a high capacity and
2q w xcontain low and high affinity Ca binding sites 56 ,
the low affinity Ca2q binding sites bind Ca2q with a
w xK of about 1–2 mM 58 .D
There is evidence that cellular vesicles in neuronal
or exocrine cells also contain calcium transport pro-
w xteins as well as CaPs in their lumen 59 . In isolated
pancreatic zymogen granules IP and cyclic ADP-3
 . 2qribose cADPR have been shown to induce a Ca
w xrelease 60 ; this release is integrated in the cellular
2q w xCa signalling 46,61 . In pancreatic acinar cells the
different Ca2q storage compartments seem to be
arranged like an intracellular tubule, enabling Ca2q
tunneling from the place of entry, usually the basolat-
eral cell pole, towards the storage site at the apical
w xcell pole 62 .
2.1.2. Intracellular calcium release channels
For Ca2q release from intracellular stores, two
different channels, the IP receptor-linked and the3
ryanodine receptor-linked channel, have been charac-
w xterized 63–65 . Their structural and functional prop-
erties are presented in Table 1. The IP receptor3
contains four subunits of around 320 kDa, each form-
ing a tetramer. It is inserted in the ER membrane by
six membrane spanning regions. Both, the N-terminus
and the C-terminus of the protein are facing the
cytosol, the latter contains the IP binding region and3
the domains for Ca2q and adenine nucleotide modu-
lation. At least three genes code for the three differ-
ent receptor types: Receptor types II and III share
homology of 70 and 62%, respectively, with the type
w xI receptor 66 . Furthermore, there exist various iso-
w xforms of the IP receptor 63 .3
The functional importance of this IP receptor3
heterogeneity and its role during tissue development
or during pathogenic processes remains to be eluci-
dated. The IP receptor seems to be present in almost3
all vertebrate cells but the degree of expression varies.
w x w xOlfactory cells 67 and lymphocytes 68 express
another IP receptor subtype in their plasma mem-3
brane whose nature and functional role remain hith-
erto unclear.
Binding of IP , which is produced by the G-pro-3
tein-activated phospholipase C, triggers the release of
Ca2q from internal stores. There is an IP binding3
site on every subunit, the number of IP molecules3
w xrequired to open the channel is unclear 69–71 .
Pharmacological inhibitors of the IP channel are3
w xheparin and caffeine 72 . Protein kinase A, protein
kinase C, calmodulin-dependent protein kinase II, as
well as a G-protein-dependent mechanism modulate
w xchannel activity by phosphorylation 73,74 . IP -in-3
duced Ca2q release at increasing Ca2q concentrations
follows a bell-shaped curve maximum open proba-
.bility at 0.2 mM with positive feedback at lower
Ca2q concentrations and negative feedback at higher
2q  . w xCa concentrations above 0.5 mM 75 . Finally,
the IP -evoked Ca2q release seems to be controlled3
2q 2q w xby the Ca content within the Ca store 76 .
Table 1
Intracellular Ca2q channels
IP Ryanodine3
receptor receptor
Molecular mass of subunit 320 kDa 560 kDa
Structure tetramer tetramer
Conductance 10–20 pS 100 pS
2q 2q .Activators IP , Ca cADP-ribose, ryanodine -10 mM , Ca , heparin, caffeine,3
 .imperatoxin activator only skeletal form , adenine nucleotides
2q 2q 2q .Inhibitors heparin, Ca , caffeine ryanodine )10 mM , Ca , ruthenium red, Mg ,
imperatoxin inhibitor
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The second important intracellular Ca2q channel is
w xthe ryanodine channel 77–79 . The four subunits
have a molecular weight of 564 kDa each. Around
95% of the protein towards the N-terminus are lo-
cated in the cytosol, the other 5% comprise a mem-
brane-spanning region with the C-terminus facing the
cytosol, too. The number of transmembrane helices
 .4–12 is still controversial. The cytosolic part per-
mits a close spatial relationship between the Ca2q
 .channel and the dihydropyridine DHPR receptor in
the T-tubule of the striated muscle cell plasma mem-
w xbrane essential for stimulus contraction coupling 80 .
There exist three isoforms of the ryanodine recep-
tor: skeletal, cardiac, and brainrsmooth muscle ryan-
w xodine receptors 81,82 . They are products of three
different genes. Comparison of the amino acid se-
quences of the different tissue isoforms within one
species revealed a homology of about 60–70%, which
is lower than the homology of identical isoforms
 .from different species around 90% .
The ryanodine receptor is a cation-selective chan-
nel with high conductances for both monovalent 600
.  .pS and divalent 180 pS ions. At 0.01–10 mM
ryanodine stimulates Ca2q release, higher concentra-
 . 2q w xtions )10 mM inhibit Ca release 83 , correlat-
ing with low and high affinity binding sites for
ryanodine. Ryanodine receptors may be opened by
depolarization, a property important for the functional
coupling of the DHPRrryanodine receptor complex.
w 2qxThe ryanodine receptor is also activated by Ca i
from 10 nM to 1 mM; this forms the basis of the
 .calcium-induced calcium release CICR . Higher in-
2q  y5 .tracellular Ca concentrations )10 M are in-
hibitory, suggesting various sites with different Ca2q
w xaffinity in the cytosolic domains of the receptor 75 .
The Ca2q concentration within the Ca2q store also
2q w xaffects Ca release 84 , probably mediated by
calsequestrin. ATP and phosphorylation by Ca2q-de-
w xpendent calmodulin kinase stimulate 85 , calmodulin
2q w x w xand Mg 86 exert an inhibitory effect 87 . Two
scorpion toxins selectively act on ryanodine receptor
subtypes, imperatoxin as inhibitor and imperatoxin as
activator. The former inhibits ryanodine binding and
activity of skeletal and cardiac ryanodine receptors;
the latter activates the skeletal ryanodine receptor
w xsubtype 88 .
In some cells the physiological effector molecule
for the ryanodine receptor is cyclic ADP-ribose
 . w xcADPR 89,90 . cADPR is generated from b-nico-
tinamide–adenine dinucleotide and activates the car-
diac ryanodine receptor at concentrations of about 20
w xnM in sea urchin eggs 89 . In other cells higher
doses of cADPR are necessary to induce Ca2q re-
lease. Moreover, cADPR and calmodulin act syner-
w xgistically during sensitization of CICR 91 . There-
fore, the exact role of cADPR—messenger for or
modulator of the ryanodine receptor—seems to vary
w xamong different cells 92 .
Several proteins have been shown to be involved
in the function of ryanodine receptors: the CaP an-
nexin VI, S-100, calpain, and the immunophilin
w xFK506 binding protein 93 . The physiological role of
the latter is unclear. Upon binding of the immuno-
suppressive drugs FK506 or rapamycin the im-
munophilin dissociates from the ryanodine receptor
w xthereby modulating its activity 94,95 .
2.1.3. Plasma membrane calcium channels
Plasma membrane Ca2q channels have been clas-
 .sified according to their gating mechanisms Fig. 2
w x 2q37,39,96,97 . Ca entry can be activated either by
voltage changes, by binding of certain exogenous and
endogenous transmitters or simply by membrane
stretch. In most cells more than one type of Ca2q
w xinflux pathway can be found 98 .
According to their electrical behaviour and sensi-
tivity to inhibitors the voltage-dependent Ca2q chan-
 . nels VOC are classified into L-type long lasting—
.  .large capacitance , T-type transient , N-type
 .neither , and P-type. L-type channels as well as
Fig. 2. Schematic diagram of various types of plasma membrane
Ca2q channels gating a Ca2q influx down the electrochemical
gradient. VOC s voltage-operated channel, SMOC s second
messenger-operated channel, ROCs receptor-operated channel,
SCA sstretch-activated channel.
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N-type channels are activated and deactivated in a
mV range closer to positive potentials than the T-type
w xchannels 99 . Since T-type channels exhibit only a
short opening time, it has been proposed that they
w x 2qmay serve as pacemakers 100 . The Ba conduc-
w xtance is about 25 pS for L-type channels 101 , about
9 pS for T-type channels and about 13 pS for N-type
w x 2qchannels 102 . All types accept, besides Ca , diva-
lent ions such as Ba2q and Sr 2q. Usually, Ba2q and
Sr 2q inhibit Ca2q conductance. However, under cer-
tain circumstances, the conductivity of L-type chan-
nels is improved by Ba2qrSr 2q. The sensitivity of
the voltage-dependent Ca2q channels towards various
pharmacological agents is markedly different. Com-
pounds of the dihydropyridine, benzothiazepine, or
phenylalkylamine group block L-type channels, most
probably by switching the channels to a different
w xgating mode 103 . Dihydropyridine increases the
opening probability of L-type, but not of T- or N-type
w xchannels 100 . Cadmium blocks N- and T-type chan-
w xnels 104 .
v-Conotoxin, isolated from the marine snail Conus
geographus, inhibits N-type channels and neuronal
2q w xL-type Ca channels 104 , but fails to inhibit mus-
cle L-type Ca2q channels. Taicotorcin, a snake venom
 . 2qOxyruroms S. Sutellats inhibits cardiac L-type Ca
channels, suggesting that different subtypes of the
L-type group might exist. Physiologically, cardiac
L-type channels are regulated by b-adrenoreceptor
agonists via cAMP-induced phosphorylation and via
w x w 2qxstimulation by G-proteins 105 . Elevated Ca in-i
hibits the L-type current in various tissues, whereas
the T-type currents in canine ventricular and Purkinje
w x w 2qxcells are enhanced 106 . The inhibition by Ca isi
not observed in L-type channels reconstituted in lipid
bilayers, suggesting the involvement of an cytoplas-
mic factor or channelrmembranercytoskeleton inter-
w xactions for the inhibitory effect 107,108 . Similar
factors seem to be responsible for the instability of
reconstituted L-type channels compared to T-type
w xchannels 107,109 .
Muscle L-type Ca2q channels consist of five sub-
 .units: an a1-subunit 155–200 kDa , an a 2-subunit
 .  .130–150 kDa , a b-subunit 52–65 kDa , a d-sub-
 .  .unit 24–33 kDa , and a g-subunit 30–33 kDa . The
major channel-forming polypeptide is the a1-sub-
unit, probably responsible for both ion flux and volt-
w x 2qage sensing 110,111 . The receptors for organic Ca
channel blockers as well as the phosphorylation sites
for various kinases are located on the a1-subunit.
Both, a 2- and g-subunits contain membrane span-
ning domains, whereas d- and b-subunits are at-
tached extracellularly and intracellularly, respec-
tively. The b-subunit regulates Ca2q channel activity
w x112 .
L-type and T-type Ca2q channels are predomi-
nantly found in electrically active tissue. N-type
channels seem to be restricted to neuronal cells, with
preference to the nerve terminals, where they are
involved in the negative feedback loop of neurotrans-
w xmitter release 113 . Usually voltage-gated channels
of different type are present in the same tissue or in
w xthe same cell 100 . Moreover, within one cell volt-
age-gated Ca2q channels can be regionally concen-
w xtrated 114 .
Ligand gated Ca2q channels can be subdivided
 .into receptor-operated channels ROC and second
 . w xmessenger-operated channels SMOC 115 . In the
ROCs receptor and ion gating subunit are part of the
same molecule and binding of a ligand to the receptor
 2qon the cell surface induces a cation current Ca and
q. w xNa in the range of 5–50 pS 116 . ROCs are
present in excitable cells, such as the glutamate-
activated channel in vertebrate neurons or the ATP-
activated channel in smooth cardiac and skeletal mus-
w x w xcle cells 117–119 , sensory neurons 120 ,
w x w xmacrophages 121 , and exocrine cells 122 .
SMOCs are gated by a messenger acting intra-
cellularly. Activators or modulators include G-pro-
w xteins, protein kinases 123–126 , IP or its degrada-3
w x 2qtion products 127,128 . The activity of the Ca
channel is closely related to the filling state of the
2q w xintracellular Ca stores 129–140 ; depletion often
stimulates a Ca2q influx, causing the so-called capac-
2q w x 2qitative Ca influx 132–135 . The Ca release-
 .activated channel CRAC is highly selective for
2q w xCa with a conductance of about 1 pS 136 . The
mechanism how the channels are activated might
involve a direct interaction of intracellular Ca2q re-
w xlease channels with CRAC 137 or a small molecule
 .such as a small G-protein released together with
Ca2q from the intracellular store that transduces the
w x 2qsignal to the membrane 138–141 . Ca entry via
w xCRACs is further modulated by cGMP 142 and
w xvarious kinases 143–145 . The state of filling of the
2q w xCa stores thereby regulates the cGMP levels 146 .
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Studies on Drosophila photoreceptor protein which
are potential candidates for capacitive Ca2q entry
pathways can be expected to elucidate the coupling
w xmechanism in more detail 147–149 .
 .Stretch-activated calcium channels SAC carry
Ca2q as well as other cations. Their open probability
w xis also affected by the membrane potential 150 . One
particular property of SACs is the sensitivity to
w xgadolinium 151 . Usually, SACs are involved in cell
volume regulation.
Within one cell, multiple pathways for Ca2q entry
can be present; their interrelation and regulation in
w xconcert are poorly understood 152 .
2.2. Calcium decreasing mechanisms
The maintenance of Ca2q gradients across the
plasma membrane and the membranes of intracellular
stores requires metabolic energy. The transmembrane
accumulation is achieved either by primary acti˝e
Ca2q-ATPases or by secondary acti˝e NaqrCa2q
exchangers, which are driven by the Naq gradient
established across the plasma membrane by the
NaqrKq pump and the membrane potential.
2.2.1. Calcium-ATPases
There are two different Ca2q pump superfamilies,
the sarcoplasmicrendoplasmic reticulum Ca2q-
 . w xATPase family SERCA 153,154 and the plasma
2q  .membrane Ca -ATPase family PMCA .
Three genes are encoding the SERCA pumps
w x155,156 . Because of alternative splicing, both
SERCA 1 and 2 have two isoforms. The isoforms
differ in their tissue distribution. SERCA 1 is found
in fast twitch skeletal muscle and the expression of
SERCA 1a and 1b is developmentally regulated
w x155,157 . SERCA 2a is expressed mainly in heart
and slow twitch skeletal muscle, SERCA 2b is found
in nearly every tissue. Large and small intestine,
spleen and lung are the preferential tissues for SERCA
3. It is also found in brain, stomach, uterus, skeletal
w xmuscle, and heart 156 . The expression of SERCA 1
w xis controlled by hormones and growth factors 158 .
The resulting five different isoforms have molecular
weights varying from 100–115 kDa. The homology
of the isoforms varies between 75 and 85%. The
arrangement in the plasma membrane and the do-
mains for putative Ca2q binding are highly conserved
w x among the isoforms 155 . There seem to be 10 11
.for SERCA 2b transmembrane domains, a small
segment inside the organelle and a big cytosolic part
containing the calcium binding domain, the ATP
binding domain, and the phosphorylation site during
2q w x 2qCa binding 159 . The Ca binding site differs
from the well-known EF-hand in the Ca2q binding
protein. Transmembrane helices 4, 5, 6, and 8 appear
2q w xto be involved in Ca binding 160 .
Two moles of Ca2q ions are transported per mole
ATP. The affinity constant varies between 0.4 and
1.1 mM and the maximum velocity between 0.5 and
w x5 mmolrmg proteinrmin 161,162 . The affinity for
Ca2q can be greatly enhanced by phospholamban.
This homopentameric molecule, consisting of sub-
units with a molecular weight of 6 kDa, regulates
SERCA 1 and 2. Upon phosphorylation, the in-
hibitory action of phospholamban on the pump is
abolished and the Ca2q affinity of the pump is in-
creased. Thapsigargin, a tumor-promoting sesquiter-
pene lactone, is a highly effective and specific in-
w xhibitor of the SERCAs 163,164 , whereas heavy
metals like Cd2q inhibit Ca2q pumps both in the
w xplasma membrane and intracellular stores 165,166 .
Four genes have been demonstrated to encode the
2q  .plasma membrane Ca -ATPase PMCA . There ex-
w xist several isoforms due to alternate splicing 167 .
The molecular weights range from 127–136 kDa.
The expression of the PMCAs in various tissues is
 .quite different Table 1 . PMCA 1 transcripts have
been detected in nearly all tissues, whereas the ex-
pression of PMCA 2–4 mRNA is highest in brain
w x168 .
The PMCAs belong to the P-type ion pumps with
a stoichiometry of 1 mole Ca2q transported per mole
w xATP split 152 . There is evidence for 10 transmem-
brane domains connected by small extracellular loops
and large intracellular loops that represent nearly
80% of the pump mass. The latter contain the ATP
binding site, the aspartate phosphate binding site, the
calmodulin binding domains, and the phosphorylation
w xsites for protein kinases A and C 169,170 . The
binding of calmodulin results mainly in an increase
2q w xof the Ca affinity 171 but there is also evidence
for an inhibitory effect of calmodulin binding due to
2q w xspatial obstruction of the Ca binding site 172 .
The Ca2q affinity of the pump increases 40-fold upon
w xcalmodulin activation 173 . PMCA are also directly
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w xactivated by stimulating agonists 174 . In vitro, the
Ca2q-activated intracellular protease calpain can
w xstimulate the pump by limited proteolysis 175,176 .
In vivo, the situation remains to be elucidated since
calmodulin can slow down proteolysis and change
w xthe sites of protein cleavage 176 .
2.2.2. Sodiumrcalcium exchanger
The NaqrCa2q exchanger has been found in a
w xnumber of cells and tissues 177–181 . Several iso-
forms of the classical NaqrCa2q exchanger have
been cloned from at least three different genes NCX
. w x1–3 182,183 .
The exchanger from canine cardiac SR is a
polypeptide with a molecular weight of about 110
w xkDa 184,185 . The proposed topology of the
NaqrCa2q exchanger consists of 11 transmembrane
segments. An intracellular loop between segments 5
and 6 seems of particular importance. It contains an
inhibitory region and a regulatory site with a high
Ca2q affinity. The former is involved in the Naq-de-
w xpendent inactivation of the exchanger 183,186 .
The exchanger has a stoichiometry of 3 Naq:1
2q w xCa 187 . Its function is dependent on an intact
w x qactin cytoskeleton 188 . In addition to Na and
Ca2q, the activity of the antiporter is modulated by
w x 2q w xATP 189 , Mg 190,191 , and hydrogen ions
w x192–194 . The effect of protons is asymmetric—in-
hibition at the cytoplasmic side of the transporter and
w xstimulation at the periplasmic side 195 . Moreover,
part of the inhibition requires the presence of Naq.
The functional consequences of this pH sensitivity
are not yet clear.
The NaqrCa2q exchanger can operate in reverse
w x196,197 . This reversed mode may have physio-
logical implications, e.g., for heart muscle contrac-
tion, in that it can trigger Ca2q release from SR in
parallel to the voltage-dependent Ca2q channels
w x198–200 .
The relative importance of the NaqrCa2q ex-
changer in adjusting and maintaining cellular Ca2q
levels varies from cell to cell. In cells that undergo
massive intracellular Ca2q changes, like heart cells,
the high capacity NaqrCa2q exchanger plays the
dominant role. When a fine adjustment at low Ca2q
levels is necessary, the Ca2q-ATPases seem to be
w xmore important 201–203 .
2.3. Calcium buffers
The role of intracellular Ca2q buffers in determin-
w 2qxing Ca are often neglected. Their importancei
becomes evident by performing a short calculation.
w 2qxBasal Ca is between 50–200 nM, increasing toi
around 1–1.5 mM after hormonal stimulation. How-
ever, from a total cellular Ca2q content of around 12
nmolrmg protein around 25% can be released by
hormones, which should result in an increase in
w 2qx w xCa to 0.5 to 1 mM 28 . Thus, during stimulationi
only a small portion of the released Ca2q remains as
free Ca2q, most is bound to Ca2q buffers. In chro-
w xmaffin cells Neher and Augustine 204 determined
that 98–99% of the Ca2q entering the cell is taken up
by endogenous Ca2q buffers.
Calcium buffers can be subdivided into molecular
buffers, represented by the cytosolic CaP and or-
ganelle buffers, mainly represented by mitochondria
and ER. CaP have high or low affinity binding sites.
CaP with high affinity binding sites are present in
 .low concentrations low capacity , whereas intra-
cellular concentrations of low affinity CaP are much
 . 2qhigher high capacity . Ca binding to high affinity
binding sites often induces changes of the protein
structure, thereby evoking certain cellular responses
w x27,205 .
Within the cell there are inorganic, small organic,
and macromolecular Ca2q ligands. Aside from their
role in the formation of the skeletal structure, Ca2q
salts play a role under pathological conditions, when
inflammation-induced changes in the microenviron-
ment, like pH, ionic strength lead to a formation of
w xmicroprecipitates and stones 206 . L-glutamate, cit-
rate, and ATP are examples of small organic Ca2q
ligands; macromolecular ligands are calmodulin,
calsequestrin, etc. Total Ca2q buffer capacity has
been determined in human neutrophils to be around
0.76 mM with an apparent single dissociation con-
w xstant of 0.55 mM 207 .
In Table 2, Ca2q buffering molecules and their
Ca2q affinity are compiled. The CaP parvalbumin, a
muscle protein from marine organisms, has been
studied extensively. These molecules can bind up to
four Ca2q ions, like troponin and calmodulin
w x 2q217,209 . A Ca binding domain consists of an
amino acid loop together with two helices, the so-
called EF-hand. In Ca2q binding, the conformation of
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Table 2
Intracellular Ca2q ligands
Ligand pK Approx. mol. wt. Refsd
w xCitrate 3.5 249 208
w xGlutamate 1.4 144 208
4y w xATP 4.1 502 208
w xCalmodulin 5.5–6.7 16,700 208
w xTroponin C 5–7 18,000 209,210
2q w xIntestinal Ca 6.5 88,000 211
binding protein
w xCalpactin I 4–5.3 49,000 212
w xCalpactin II 5 39,000 212
w xCalelectrin 4–5 35,000–67,000 213
w xProtein II 4.6 32,500 214
w xSynexin 3.7 47,000 215
w xGelsolin 2–2.7 216
the protein changes, exposing a hydrophobic region,
enables the protein to interact with Ca2q pumps, ion
w xchannels 218 , the cytoskeleton, or a variety of ki-
w x w xnases 219 and phosphatases 220 . Molecules con-
taining such Ca2q binding domains, like the intestinal
w xCaP 221 or the S-100 protein belong to the
‘calmodulin superfamily’ of CaPs. Their Ca2q affini-
w 2qxties are close to Ca levels during cellular stimu-i
w xlation 222 .
A second class of CaPs Calpactin I and II, protein
II, calelectrin, and synexin I—all categorized into the
.annexin group show a calcium-dependent reversible
binding to membranous or cytoskeletal structures
w x 2q223 . Their Ca affinity is low, with a K of aboutD
w x10 to 100 mM 224 . However, in the presence of
specific phospholipids, the Ca2q affinity is greatly
increased and Ca2q ions bind in a cooperative man-
w xner 214,225 . Their physiological role may be to
w xregulate cell growth 226 as well as membrane fu-
w xsion 227 .
The characteristic structure of this second class of
CaP is a 70–72 amino acid chain, which can be
repeated up to four times and shows a 30% similarity
w xwith a few invariant residues 228 . The structure of
the Ca2q binding domain seems to be distinct from
the EF-hand of calmodulins.
The contributions of different Ca2q ligands to
cellular Ca2q buffering can be estimated in compar-
ing citrate and calmodulin. The intracellular concen-
tration of the low affinity Ca2q buffer citrate is
approximately 0.5 mM compared to the concentration
 .of 20 mM functional binding capacity 80 mM of
the high affinity Ca2q buffer calmodulin. Under rest-
w 2qxing conditions, at 0.1 mM Ca , calmodulin cani
bind around 200 times more Ca2q than citrate and 80
times the amount of free Ca2q. With increasing
w 2qx 2qCa the ratio changes: at 5 mM Ca 80 timesi
more Ca2q is bound to calmodulin than to citrate
w x208 . The high affinity buffers operate most effec-
w 2qxtively in a range of 1–10 mM Ca , values slightlyi
above the upper range of concentrations reported for
hormone-induced Ca2q peaks. The upper limit of 10
mM might be important in certain cellular regions,
e.g., subplasmalemmal areas, where extreme local
w xchanges have been observed 229 .
Restriction of a Ca2q signal to this range is of vital
interest to the cell. Elevation above this level can lead
to cellular destruction, e.g., by activation of calpains,
Ca2q-dependent cysteine proteases, with a K forD
Ca2q of about 30 mM for type I and 500 mM for
w xtype II calpain 230,231 .
Finally, a few comments on intracellular or-
ganelles and their role as Ca2q buffers. We will focus
here on mitochondria since ER has been discussed
before. Different intramitochondrial pools exist that
can be distinguished on the basis of their sensitivity
w xto the metabolic inhibitors, FCCP and CN 232 .
These pools are involved in buffering of an extra-
mitochondrial Ca2q load and it can be calculated that
around 30% of the total cellular Ca2q load can be
w xbuffered by mitochondria 233 . Recent results, how-
ever, using aequorin targeted to mitochondria, sug-
gest a rather minor role for mitochondria in Ca2q
w xbuffering 234 .
Ca2q uptake into mitochondria is mediated by a
uniporter driven by the electrochemical gradient. The
Ca2q transport capacity is high and can be inhibited
by ruthenium red and lanthanides. Calcium efflux is
mediated by two different pathways, a Naq-depen-
dent pathway, most probably a NaqrCa2q ex-
q w xchanger, and a Na -independent pathway 235,236 .
2.4. Calcium signalling pattern
Electrical and humoral stimuli can evoke a number
of different responses of intracellular Ca2q depending
on the relative activities of Ca2q-increasing and de-
creasing mechanisms as well as extracellular factors
w xlike type and concentration of stimulus 46 . The
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changes in intracellular Ca2q may be uniform through
the whole cell or may be restricted to certain areas.
Furthermore, the changes can vary throughout stimu-
lation, resulting in spatial and temporal signalling
patterns.
The simplest response is a uniform Ca2q increase
within the whole cell, usually as a ‘peak and plateau’
sequence. In pancreatic acinar cells, as in many other
cells, this sequence can be initiated by supramaximal
 . w xdoses of agonists Fig. 3 237 . Receptor occupation
and G-protein-linked activation of phospholipase C
result in the formation of IP , which releases Ca2q3
 .from intracellular stores speak phase , followed by
a sustained influx of extracellular Ca2q across the
 . w xplasma membrane splateau phase 238 . Store de-
pletion seems to trigger the sustained Ca2q influx
either by a kind of diffusible messenger, which seems
w xto be phosphatase sensitive 139,239 , or by a particu-
lar arrangement of plasma membrane channels and
intracellular Ca2q stores. After termination of stimu-
lation, intracellular Ca2q release and transmembrane
influx cease and Ca2q is sequestered back into the
intracellular stores or extruded out of the cell. How-
ever, there exist ample modifications; e.g., in muscle
cells Ca2q pools of SR are depleted by the interaction
of the voltage sensor of the dihydropyridine receptor
w xand the intracellular ryanodine channel 240 . Like-
wise, in several cases intracellular stores are not
involved in the Ca2q response and changes of intra-
cellular Ca2q are solely induced by movements of
2q w xCa across the plasma membrane 241 .
Spatial Ca2q responses are manifested as Ca2q
waves. They have been described first in eggs upon
fertilization. Ca2q waves have also been found in
heart muscle cells, pancreatic acinar cells, hepato-
cytes, and endothelial cells. There are slow and fast
Ca2q waves with propagation rates ranging from
w xmmrs to 100 mmrs 242 . Fast waves usually cross
Fig. 3. Effect of different agonists and concentrations on intra-
cellular Ca2q signals in single pancreatic acinar cells. A supra-
 .maximal concentration of acetylcholine ACH, 100 mM results
in a peak plateau sequence of intracellular Ca2q concentration
 .  .A . A physiological concentration of ACH 500 nM results in
2q  .cytosolic Ca oscillations B . The frequency of oscillations can
be modulated by different concentration of secretagogues, e.g.,
 .cholecystokinin C .
the whole cell, whereas slow waves propagate within
the subplasmalemmal area. Another distinction is
based on the steepness of the Ca2q change at the
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wave front. In cardiac cells, a sudden sharp increase
of Ca2q concentration at the wavefront has been
demonstrated, whereas in hepatocytes, Ca2q concen-
tration rises progressively in the direction of wave
w x 2qpropagation 243 . Moreover, when Ca wave prop-
agation occurs, spiral Ca2q waves can be induced
w xalong the wave front 244 . Several models have been
developed to explain these observations. The basis of
Ca2q wave propagation is similar to a reaction–diffu-
w xsion mechanism 245–247 .
Ca2q waves are frequently associated with Ca2q
oscillations. Ca2q oscillations are highly variable in
frequency, amplitude, and shape of the Ca2q spikes
potentially coding for huge amounts of information
w x248 . This variability depends on cell types and kind
 . wand concentration of the stimulant Fig. 3 237,249–
x251 . Within one cell type the same agonist can
w xevoke different oscillation patterns 252 . Several dif-
ferent models have been proposed to explain the
2q w xoccurrence of Ca oscillations 253–255 . It has
been suggested that Ca2q oscillations are caused by
periodic changes in IP concentrations via feedback3
by Ca2q and PKC. However, alternating IP concen-3
trations have not been demonstrated so far, instead,
constant IP concentrations using a non-metaboliz-3
able IP analog have been shown to evoke Ca2q3
w x 2qoscillations 256 . Like in Ca waves, an important
underlying principle of Ca2q oscillations seems to be
w xcalcium-induced calcium release 257 . An initial
Ca2q release provokes a further Ca2q increase; how-
ever, above a certain concentration a negative feed-
back occurs. Because of the bell-shaped Ca2q depen-
dency of its activity, the intracellular Ca2q release
channel closes and Ca2q is sequestered until the next
cycle starts. The inhibitory action of Ca2q alone does
not seem to be sufficient for explanation. There is
evidence for stores of different IP sensitivity or IP3 3
w xreceptor density in pancreatic acinar cells 45,258
which may be the cause for the spatially restricted
2q w xCa signals. Recently, Thorn et al. 259 demon-
strated that a localized Ca2q spike is the result of the
coordinated action of multiple single Ca2q release
events. Localized ‘hot spots’ resembling the local
w x 2qpuffs shown in Xenopus oocytes 260 initiate Ca
release from surrounding regions. Moreover, the
repetitive temporal Ca2q signalling patterns as well
as the Ca2q waves are influenced by the activity of
2q w xthe Ca sequestering pumps 261,262 and the ex-
2q w xtent of transmembrane Ca movement 263 . Fi-
nally, Ca2q oscillations are also modulated by inter-
w xcellular communication via gap junctions 264,265 .
3. Calcium homeostasis and calcium signalling in
disease states
During recent years the role of Ca2q in the devel-
opment and maintenance of disease states has been
demonstrated in a number of instances. While its role
has long been implicated in cardiovascular diseases,
there is now increasing evidence for Ca2q being
involved also in other pathophysiological processes,
such as inflammation, stroke, diabetes, and tumor
spreading. Within the scope of this review it is not
possible to discuss all these cases in detail. Therefore,
the authors will concentrate on four different exam-
ples of disturbed cellular Ca2q homeostasis: inflam-
matory processes, heart diseases, hypertension, and
neurologic disorders.
3.1. Inflammatory processes
Inflammation is a process in which several cell
types are involved. In a simplified model, a physical
or chemical factor damages cells of a certain organ or
tissue. This damage activates the immune system
represented by granulocytes and lymphocytes. The
tissue damage plus the immune response yields the
inflammatory process which may be restricted to an
area or organ or may have systemic effects like in
sepsis. There are several examples that disturbances
w 2qxof Ca represent an early feature of inflammationi
and may have consequences on maintenance of
pathological state. In the following, the role of Ca2q
in the impairment of cellular integrity by physical,
chemical, or biological irritation will be highlighted
first. Then, the Ca2q-dependent responses of the im-
mune system will be discussed.
3.1.1. Tissue damage
Any agent that is able to disrupt plasma membrane
w 2qxintegrity will cause an increase in Ca . This is thei
case for chemical irritation of cells, e.g., by certain
antibiotics like the Ca2q ionophores. However, there
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are more specific toxins. The B-subunit of the cholera
w 2qxtoxin evokes an increase of Ca in lymphocytesi
without affecting IP levels or the PKC pathway3
w x266 . Clostridium difficile toxin A application results
w 2qx w xin an increase in Ca in neutrophils 267 , fol-i
w xlowed by a disassembly of cytoskeleton 268 .
Hemolysin producing Escherichia coli strains induce
2q w xa massive Ca increase in human platelets 269 and
a number of hepatoxins, like bromobenzene or ac-
etaminophen, disrupt cellular Ca2q homeostasis
w x270,271 , thereby causing blebbing of plasma mem-
w xbrane 272 . One reason is the inhibition of the
plasma membrane Ca2q pump, causing saturation of
intracellular Ca2q buffers, followed by an increase in
w 2qxCa and depletion of intracellular ATP associatedi
with a derangement of the cellular cytoskeleton
w x273,274 . Most likely, this mechanism is involved
w xalso in heavy metal cytotoxicity 275 .
For the CCl -induced liver cell necrosis, a role of4
w 2qxCa has also been demonstrated. CCl initiallyi 4
impairs the integrity of a variety of Ca2q stores and
Ca2q buffer organelles. Later, the plasma membrane
becomes leaky, permitting an additional massive Ca2q
influx, a process in which activation of phospholipase
w x 2qA2 seems to be involved 276 . Likewise Hg ,
besides inhibiting the plasma membrane Ca2q pump,
releases Ca2q from intracellular stores that are dis-
w xtinct from thapsigargin-sensitive stores 277 .
w xIn a duct ligation-induced pancreatitis 278 in rats,
it could be demonstrated that increases in basal
w 2qxCa represents an early sign of acute pancreatitisi
w x 2q279 . Furthermore, Ca -dependent hormone and se-
cretory functions are impaired. The same phe-
nomenon is observed in the cerulein hyperstimulation
w xmodel of acute pancreatitis 280 where the character-
istic spatial Ca2q signalling pattern during hormone
w xstimulation is lost 281 . Interestingly, the capacity of
Ca2q stores in normal and inflamed cells is the same,
suggesting a defect at the level of receptorrG-protein
interaction or the IP channels.3
Inflammation also affects the main cellular redox
 . w x 2qsystem, glutathione GSH 282 . Ca and GSH
w 2qxlevels influence each other. Increased Ca lowersi
w xthe cellular GSH content 283 ; decreased GSH levels
2q w xincrease Ca entry into the cell 270 . On the other
hand, exogenous GSH inhibits the Ca2q ionophore-
mediated Ca2q entry or thapsigargin-evoked Ca2q
w xinflux in gastric mucosal cells 284 . In human T-cells
the thapsigargin-induced Ca2q influx is, however, not
w x 2qaffected by GSH levels 285 . Instead, Ca influx
stimulated via the T-cell receptor decreases with de-
creasing GSH concentration. Such mechanism might
act as a switch between an antigenic mode—resulting
in cell proliferation—and an inflammatory mode—
resulting in secretion of inflammatory mediators.
Thereby, GSH probably modifies the signal transduc-
tion pathway at the level of the tyrosine kinase.
3.1.2. Immune response
In order to orchestrate the different cell popula-
tions involved in inflammation—epithelial and en-
dothelial cells, macrophages, neutrophils, eosinophils,
basophils, and lymphocytes—a number of biologi-
cally highly potent mediators like cytokines and
arachidonic acid metabolites are utilized. Ca2q is
involved in the stimulus-induced secretion of several
 .mediators. Lipopolysaccharide LPS -induced secre-
 .tion of interleukin IL -1a , IL-1b and IL-10 is af-
fected by Ca2q and calmodulin inhibitors in murine
peritoneal macrophages. Both LPS and Anti-IgE-
evoked IL-6 production in peritoneal mast cells are
2q w xdependent on the presence of extracellular Ca 286 .
IL-4 transcription of the CD4q helper cell subset
2q w xTh2 depends solely on the presence of Ca 287 .
Interestingly, gene expression of T-lymphocytes
w 2qxvaries not with the way by which changes in Ca i
w x w 2qxare evoked 288 . But a Ca increase per se doesi
not seem to be sufficient for cytokine release in every
w xcase 289,290 since the T-lymphocyte synthesis and
secretion of interleukin-2 is only partially controlled
2q w xby a continuous Ca influx 131,291 . The forma-
tion of leukotrienes in mast cells, eosinophils and
w xbasophils 292 as well as in epithelial cells like
w xgastric chief cells 293 through the 5-lipoxygenase
pathway is promoted by extracellular Ca2q. This
might have important implications for asthmatic and
other allergic diseases where an eosinophilic hyperac-
tivity is thought to be the underlying mechanism.
In neutrophils of patients with Crohn’s disease, the
w 2qxleukotriene-induced changes in Ca are impairedi
w x 2q294 . Moreover, impaired Ca signalling in leuko-
cytes is a common feature of chronic inflammatory
diseases. For example, in active rheumatoid arthrosis,
w 2qxchanges in Ca evoked via the Fc receptors arei
w xdepressed 295 , whereas in the quiescent phase of
the disease, no defect in Ca2q signalling is observed.
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Likewise, phytohemagglutinin or anti-CD3-induced
w 2qxchanges in Ca of T-lymphocytes are affected ini
patients with inflammatory bowel disease and
w xrheumatoid arthritis 296 .
The systemic inflammatory mediator tumor necro-
sis factor a is able to impair both resting and hor-
2q w xmone-stimulated Ca levels in cell culture 297 ,
whereas other cytokines are able to enhance mobi-
2q w xlization of Ca from intracellular stores 298 .
Cytokines and related substances evoke many of
w 2qx w xtheir effects via changes in Ca 292 . The IL-3-i
promoted adhesion of human basophils to endothelia
2q w xis improved by extracellular Ca 299 . Moreover,
chemokines induce leukocyte migration by increases
w 2qx w xin Ca 300,301 . In addition, the permeabilityi
changes of endothelial cells during leukocyte evasion
are promoted by intra and extracellular Ca2q, proba-
bly mediated via integrins and cytokines, in particular
w xIL-1 302,303 . IL-1 has been shown to increase
w 2qx 2qCa by stimulating Ca influx across the plasmai
membrane. This effect depends on an intact arrange-
ment of cell–cell and IL-1 receptor–cytoskeletal in-
w xteractions 304 . Tight junctions permeability is also
increased by mobilization of Ca2q from intracellular
w xstores 305 .
w 2qxKiller cells increase Ca in their target cellsi
markedly, which induces necrosis or apoptosis
w x306,307 . Interestingly, the whole process can be
prevented by increasing the intracellular Ca2q buffer
capacity. Similar mechanisms are responsible for the
cytotoxic activity of the tumor necrosis factor a
w x308 . Although all of these responses should be
helpful in overcoming inflammation, an excessive
activation seems to be deleterious and may even
maintain the inflammatory state. This might explain
the beneficial effect of organic Ca2q channel block-
w xers in suppressing the inflammatory response 309 .
3.2. Heart failure
w 2qxIn heart muscle an excessive increase in Ca ,i
‘calcium overload’ is responsible for lesions of my-
ofibrils and mitochondria, and finally for cell death
w x310 .
The most important cause for ‘calcium overload’
is an increased permeability of the plasma membrane
for calcium, most frequently induced by perfusion
w xreduction 311 .
Cellular calcium changes during ischemia occur in
two different phases. Initially, the cellular ATP stores
are depleted since mitochondrial respiration is inhib-
ited. In parallel, the collapse of the Hq gradient
across the inner membrane of the mitochondria leads
to a release of mitochondrial Ca2q. The increase in
w 2qx 2qCa , in turn, activates Ca -stimulated ATPasesi
reducing ATP content further. In addition, proteases
w xthat degrade cellular structures are activated 312 . At
this early stage the disintegration of the membrane
barrier has no severe consequences since due to the
reduced perfusion of the extracellular space, the Ca2q
gradient across the plasma membrane diminishes.
Furthermore, ischemia-induced tissue acidosis de-
creases Ca2q entry through voltage-dependent Ca2q
w xchannels 313 . In the second phase, when reperfu-
sion of the ischemic area starts, the Ca2q gradient
across the plasma membrane is re-established. Ca2q
flows into the cells and the Ca2q extrusion capacity
w xof the cells is exceeded 314 . Moreover, the cytokine
IL-1 impairs the protective effects of protons on
2q w xCa currents during acidosis 315 . The extrusion
capacity is also decreased because the reduced Naq
gradient lowers the NaqrCa2q exchanger activity
w x q 2q316 . Moreover, a reversal of the Na rCa ex-
w 2qxchanger might increase Ca , perhaps even acti-i
w xvated by oxygen-derived free radicals 317 . Finally,
the Ca2q increase results in cellular necrosis probably
by activating a number of degrading enzymes like
ribonucleases and proteases. This model has been
confirmed by observations that the extent of cell
necrosis is markedly reduced when the massive Ca2q
influx is inhibited by application of Ca2q channel
w xblockers 318 .
w 2qxA decrease in Ca buffer capacity can alsoi
amplify the effect of the massive Ca2q influx since
application of the Ca2q chelator BAPTA, which in-
creases intracellular Ca2q buffer capacity, reduces
w xpost-ischemic ventricular fibrillations in dogs 319 .
The reduction of ATP and the modification of other
Ca2q buffering molecules might be important factors.
In heart muscle cells of patients with end-state
heart failure, a reduced availability of Ca2q has been
reported. Especially, Ca2q release and Ca2q re-up-
take from intracellular stores seem to be impaired
w x w x320,321 . Cytosolic factors 322,323 as well as de-
creased mRNA levels for the SR Ca2q release chan-
 .nel ryanodine receptor , phospholamban, and for the
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2q w xCa -ATPase isoform have been implied 324–326 .
Additional post-translational regulation cannot be ex-
cluded. Expression of ryanodine receptors was also
decreased significantly in patients with ischemic car-
diomyopathy, whereas the opposite was observed in a
w xgroup with idiopathic dilated cardiomyopathy 326 .
These findings suggest that intracellular Ca2q home-
ostasis is impaired in dilated cardiomyopathy. A re-
duced refilling of intracellular Ca2q stores during
diastole decreases the amount of Ca2q available for
the next contraction.
In end-stage heart failure, an increase of mRNA
and protein levels of the NaqrCa2q exchanger has
w xbeen observed 327 . The enhanced expression of the
exchanger may have consequences for the electrical
stability of heart tissue because late depolarizations
due to the electrogenic exchanger operation can oc-
cur. These may cause the well-known arrythmias in
patients with chronic heart failure.
The mechanisms leading to different expression
patterns of Ca2q-transporting proteins are poorly un-
derstood. From developmental studies on muscle
cells, a control of Ca2q transport proteins by mito-
w xgens and growth factors is well known 328,329 .
Calcium oscillations in cultured rat myocytes, which
depend on the presence of a ryanodine-sensitive Ca2q
release, rely on the presence of tumor growth factor
w xb 1 330 . Recently, interleukin 1b has been shown
to downregulate Ca2q-regulating genes in cultured rat
w xventricular myocytes 331 . Changes of mRNA and
protein levels during cardiac diseases might be in-
duced by similar mechanisms.
3.3. Hypertension
An important pathophysiological parameter in hy-
pertension is the increased availability of intracellular
2q w xCa 332 . This increase forms the basis for the
therapeutic use of Ca2q channel blockers like nifedip-
w x 2qine, etc. 111 . The Ca channel blockers reduce
intracellular Ca2q availability and thereby impair ex-
citation–contraction coupling in vascular smooth
muscle cells, the major determinant of vascular tone
w x333 .
Although a few studies reported unchanged or
w 2qxdecreasing values of Ca during hypertensioni
w x w 2qx334,335 the increase in Ca seems to be estab-i
lished as the major pathophysiological factor. An
w 2qxincrease in Ca has been described in platelets,i
erythrocytes, lymphocytes, aorta, and in renal cells
either in patients with hypertension or in sponta-
w xneously hypertensive rats 336–338 . The increased
level of free Ca2q can be the result of either an
increased Ca2q influx or a decreased Ca2q extrusion.
w 2qxSeveral causes for the disturbance of Ca havei
been proposed. It has been known for a long time that
hypertension is associated with decreased serum Ca2q
and a regulatory increase in parathyroid hormone
levels in extreme cases with consequences for bone
w x 2q w xmineralization 339 . Renal loss of Ca 340–343
and a decreased intestinal uptake have been observed
w x 2q344,345 . A high Ca diet often normalizes the
vascular tone especially under conditions of an en-
2q w xhanced need for Ca , like in pregnancy 346,347 .
Moreover, the relationship between intra and extra-
cellular Ca2q concentration is normalized. As an
w xunderlying mechanism 348–350 , an alteration in
activity or amount of calmodulin has been postulated
w x351 . In a number of animal studies, a loss either in
activity or amount of calmodulin has been described
in several tissues like heart, aorta, brain, or duo-
w xdenum 352–355 and a recovery of calmodulin activ-
ity in spontaneously hypertensive rats has been shown
2q w xafter a high Ca diet 353 . However, in other
models an increase in calmodulin-dependent cellular
function, such as muscle contractions or the increased
activity of the NaqrHq antiporter have been ob-
w xserved in hypertension 356,357 .
The imbalance of Naq homeostasis in primary
w xhypertension is well established 358–360 . Enhanced
Naq uptake often combined with renal Naq retention
w xrepresents an important risk factor 361–363 . In
parallel to Naq retention, intracellular Naq increases,
w 2qxwhich is accompanied by an increase in Ca ,i
probably by affecting the Ca2q extrusion systems
w x364 .
The same Ca2q-ATPase activity has been found in
erythrocytes from patients with primary hypertension
w xand in normotensive controls 365 , thus the
NaqrCa2q exchanger is most probably responsible
w 2qx w qxfor the increase in Ca . Increasing Na reducesi i
the driving forces for the antiporter, thereby partially
inhibiting the high capacity pathway of Ca2q extru-
sion. The Ca2q-ATPase is able to compensate for the
loss of activity of the antiporter only under resting
conditions and at the expense of the loading of
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Fig. 4. The extent of alterations of resting cellular Ca2q home-
ostasis after a pathological stimulus predicts the cellular outcome.
w x  .intracellular stores 366 Fig. 4 . Conversely, after
stimulation, Ca2q transients are markedly enhanced
w xand induce increased cellular responses 367 . Such
exaggerated Ca2q responsiveness is probably not re-
stricted to vascular smooth muscle cells, an enhanced
release of catecholamines from sympathetic neurons
or a suppressed production of the endothelial derived
relaxing factor nitric oxide can also contribute to the
w xenhanced vascular tone 368 .
w qxThe increase in Na is probably due to multiplei
q q  .reasons. One involves the Na rH exchanger NHE
that participates in regulation of intracellular pH, of
w xcell volume, and of cell growth 369 . At least in
phenotypic subgroups of patients with hypertension,
the transport activity of the NHE in blood cells as
w xwell as in smooth muscle cells is increased 370,371 .
w xThis abnormality seems to be genetically fixed 372
but no changes in the cDNA sequence could be
w x 2qobserved 370 . On the other hand, higher Ca
w xlevels per se stimulate the NHE activity 356,357 .
Recently, an enhanced pertussis toxin-sensitive G-
protein activity has been found in immortalized cell
w xlines from hypertensive patients 373 , suggesting a
change in the signal transduction cascade with poten-
tially stimulating effects on NHE activity and Ca2q
signalling.
w qxAnother explanation for the increase in Na isi
that in nearly 50% of patients with hypertension,
increased levels of ‘endogenous ouabain’ have been
w x q q wfound 374 that inhibits the Na ,K -ATPase 375–
x377 . In addition, chronic administration of ouabain is
able to induce hypertension in animal studies
w x378,379 , whereas short-term incubation has no ef-
2q w xfect on resting Ca levels in isolated cells 380 .
Taken together, the chronic cellular Ca2q overload
due to increased Naq levels and perhaps, altered
levels of intracellular CaPs like calmodulin, induce
higher basal activity and hyper-responsiveness in vas-
cular smooth muscle cells and blood pressure regulat-
ing endothelial or ganglion cells with a consecutive
rise in systemic blood pressure.
3.4. Neuronal damage
In no other tissue is the role of Ca2q as multifunc-
tional as in the brain. In neuronal cells there are
various types of voltage-gated channels L-, T-, N-,
.P-type channels as well as the ligand operated chan-
nels; the latter being primarily gated by glutamate. In
addition, there are second messenger operated chan-
nels which are activated on depletion of intracellular
Ca2q stores. Calcium is extruded from the cells by
the activity of active Ca2q pumps and by a NaqrCa2q
w xexchanger 381 . Besides its role as a regulator of
metabolic pathways and as a link between stimulus
and secretion, Ca2q in brain is proposed to be in-
volved in memory formation and cognitive functions
w x382 . Within this chapter, we would like to focus on
ischemic and neurodegenerative disorders.
Occlusion or rupture of a brain tissue supplying
blood vessel results in decreased perfusion with hy-
poxia and ischemia. Patients show neurologic dys-
functions ranging from paralysis of a single group of
muscles to complete unconsciousness. In the steps
leading from ischemia to neuronal cell death, Ca2q
ions plays an important integral part, summarized as
w xthe ‘exitoxicity concept’ 383–385 .
Hypoxia-induced cellular ATP depletion causes
cell depolarization resulting in the release of neuro-
transmitters, in particular the excitatory amino acid
glutamate, that accumulate in the extracellular space.
Glutamate stimulates neural cells via the
 .kainaterquisqualate KrQ and the N-methyl-D-
 .aspartate NMDA channel located on the post-
synaptic membrane. The former is permeable solely
to monovalent cations whereas the latter also trans-
ports Ca2q with a high conductance. The effects of
glutamate on cellular Ca2q signals are not restricted
to the time period when the neurotransmitter is pre-
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sent. Very short repetitive pulses of glutamate 1–3
. 2qs can evoke extremely long-lasting Ca increases,
stable for around 20 min, which depend on extracel-
2q w x  .lular Ca 386 . Prolonged exposure 15 min of
cultured neuronal cells to glutamate results in cell
death which starts about 2 h after termination of
glutamate application and also requires the presence
2q w xof extracellular Ca 387 . Furthermore, protein ki-
w xnase C activation prolongs cation influx 388 .
The relevance of these in vitro data for the situa-
tion in vivo has been demonstrated using antisense
DNA to NMDA-R1 receptor channels in rats; their
intravenous application reduced focal ischemic in-
w xfarctions 389 .
Application of NMDA antagonist fails to have
w xneuroprotective effects in global ischemia 390 ;
therefore, voltage-activated Ca2q channels and the
NaqrCa2q antiporter are likely candidates for the
2q w x 2qadditional Ca influx 391 . The increased Ca
influx might be balanced by the cells as long as there
is sufficient metabolic energy available, as for exam-
ple in a perifocal area of an infarct. In such a zone,
application of NMDA antagonists should prevent fur-
ther increases in intracellular Ca2q since the cell still
has Ca2q extrusion capacity. In contrast, when cells
are totally depleted of ATP, e.g., in the central zone
of an infarction area, the cells are flooded with Ca2q.
The potential therapeutic strategy should, therefore,
involve at least three different tools: drugs to block
the nonselective cation channels, dihydropyridine re-
ceptor antagonists, and NMDA receptor antagonists
w x382 . Recently, a novel mechanism responsible for
the increased Ca2q permeability has been described.
It involves an altered phosphoinositol cascade. Espe-
cially IP has been shown to accelerate Ca2q entry in4
w xCA1 neurons after ischemia 392,393 .
Also, changes in functional Ca2q buffer capacity
have been shown to be of importance in neurological
diseases. In rat hippocampal slices for example, cell
death can be prevented by increasing the intracellular
2q w xCa buffer capacity 394 . Similarly, electrophysio-
logical indicators of cell damage like depolarization
of resting membrane potential or loss of input resis-
tance are blunted.
Changes in expression of various CaPs have been
reported in a number of neurodegenerative diseases
w x395 . In patients with Down’s syndrome, the CaP
S100b is increased whereas immunoreactive staining
of calbindin D28K and parvalbumin is reduced in
w xcortical neurons 396 . In Parkinson’s disease, mRNA
and protein levels of calbindin D28K are decreased in
w xvarious brain regions 397 . In Alzheimer’s disease
 . w xAD a decrease in calmodulin 398 and an increase
w xin S100 protein have been described 399 .
According to studies on neuronal cells or on cells
of neuroectodermal origin, like skin fibroblasts, in
AD the intracellular Ca2q handling is impaired. Early
w 2qxobservations described a decreased basal Ca andi
a decreased response to hormonal stimulus in fibrob-
lasts; however, the total Ca2q content of the cells was
w xincreased 400 . In addition, an altered activity of the
plasma membrane Ca2q-ATPase has been reported.
In contrast, later observations suggested that Ca2q
mobilization is enhanced in AD due to the presence
of the b-amyloid protein which represents the main
component of the senile plaques. In several cellular
models, incubation with synthetic b-amyloid frag-
.ments amino acid 1–38 or 25–35 increased resting
Ca2q levels as well as Ca2q response to depolariza-
2q w xtion or to exposure of Ca ionophores 401–403 .
Furthermore, these fragments enhanced the neurotox-
icity of the excitatory amino acids as well as the
calcium-linked degenerative effect of excitoxicity
w x404 .
b-amyloid itself might act as an additional Ca2q
w xchannel, mediating influx into the cells 405 . In-
w 2qxcreased Ca , when present over an extended pe-i
riod of time, should evoke cellular adaptations. In
fact, an enhanced activity of the NaqrCa2q ex-
changer has been demonstrated in cerebral plasma
w xmembrane vesicles of AD patients 210 .
The involvement of Ca2q in the pathophysiologi-
cal cascade of AD has been suggested also by mea-
2q  .surements of Ca -activated proteinases calpain .
Their activity has been shown to be increased in the
w xbrain of deceased AD patients 215 . Likewise, their
degrading capacity could, at least in part, link eleva-
tion of cell Ca2q to cellular degeneration.
4. The transition from physiological to
pathophysiological states in calcium handling:
some general principles
In Table 3, some essential features of disease
processes with regard to basal intracellular Ca2q,
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Table 3
Multiple scenarios of altered cellular Ca2q homeostasis underlying different diseases
2q 2qw x w xCa Ca response Example Type of disease Referencei i
basal to stimulation
 . w xSteadily increasing «ry blunted by high infarction p. 32 toxin-induced cell acute 270,276,385
2q  .  .intracellular Ca death p. 27 acute pancreatitis p. 28
 . w xIncreased, stable fi hypertension p. 36 chronic 336,338
 . w xy idiopathic heart failure p. 33 chronic 320,321
 . w xNormal, stable fi Alzheimer’s disease p. 41 chronic 401
w xy chronic inflammatory diseases chronic 295,296
 .  .Crohn’s disease, rheumatoid arthritis p. 30
response of intracellular Ca2q to physiological stim-
uli and the intracellular Ca2q buffer capacity, are
compiled. When comparing the different diseases,
three different conditions can be distinguished: first,
w 2qxresting Ca is increasing continuously, finallyi
resulting in cell death initiating the acute disease.
Ca2q controlling systems are no longer able to main-
w 2qxtain Ca in a steady-state. This behaviour is ob-i
served in acute diseases like infarction or after expo-
sure to chemical or biological toxins. Second, resting
w 2qxCa is increased to a higher baseline; however,i
the increased level is more or less stable over a
w 2qxcertain period of time, i.e., Ca is still controlledi
although at a higher setpoint. This type of Ca2q
imbalance is often found in hypertension and in
w 2qxchronic diseases. And third, basal Ca levels arei
normal.
With regard to the Ca2q response to physiological
stimuli, a pathological status may result in increased
or decreased Ca2q responses. If the response is in-
creased, cellular hyperactivity can ensue as in hyper-
tension or chronic inflammatory diseases. Such hy-
peractivity always carries the risk that when the
intracellular Ca2q buffer capacity or the mechanisms
to remove Ca2q from the cytosol are impaired, intra-
cellular Ca2q might rise to levels where cellular
degradation is initiated.
Which mechanisms support an enhanced Ca2q
responsiveness? Under physiological conditions, the
2q Ca signal is ‘under control’ i.e., reaches 0.5 to 1.5
. 2qmMrl and does not exceed a certain threshold. Ca
buffers play an important role in this protection of the
cell since they absorb huge amounts of Ca2q. The
dissociation constants cover nearly the whole range
of the physiological Ca2q signals. Assuming that
functional buffer capacity i.e., intracellular buffers
2q .and Ca removing mechanism is normal, as sym-
bolized by the box in Fig. 5, activation of harmful
processes by free Ca2q is prevented.
On the left hand side of Fig. 5 a situation is
depicted where the cellular Ca2q response to stimuli
is enhanced. This may be caused by an increased
Ca2q influx or enhanced release of Ca2q from intra-
cellular stores. If the Ca2q entering the cytosol ex-
ceeds the Ca2q buffer capacity of the cell, the free
Ca2q concentration can rise above the physiological
threshold, thereby inducing cellular hyperactivity or
reactions potentially detrimental to the cell.
Cellular responsiveness can also be enhanced when
intracellular Ca2q buffer capacity is reduced as illus-
trated on the lower right hand side of Fig. 5. In this
instance, a physiological Ca2q signal might be suffi-
cient to generate Ca2q levels that exceed the thresh-
old. This may be called a relative Ca2q overload. If
in such a situation the Ca2q influx caused by stimula-
w 2qxtion is increased, nondetrimental levels of Ca i
Fig. 5. Schematic diagram demonstrating the relation of intra-
cellular free Ca2q levels and different intracellular Ca2q buffer-
 . 2qing capacities CBC . Increased Ca signals higher than CBC
 . 2qcan induce degrading processes left . Normal Ca signals may
 .give the same result when intracellular CBC is decreased right .
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can be exceeded relatively easily. During ischemia
and inflammation, a decrease of intracellular Ca2q
buffer capacity has been observed. In hypertension,
functional buffer capacity of the cell appears also to
be decreased by the reduction in calmodulin and a
reduced rate of Ca2q extrusion from the cells.
Thus far, however, only a few studies have con-
firmed a protective role of Ca2q buffers in disease
processes. One study demonstrated that cells contain-
ing higher amounts of Ca2q binding proteins are
more resistant to harmful pathological stimuli; in the
other case, an increase of Ca2q buffer capacity by
application of a Ca2q chelator resulted in a lower
w xincidence of postinfarction arrythmias 319 .
It should be noted at this point that an important
factor for the effectiveness of potentially harmful
Ca2q signals is time. Time and extent of Ca2q signal
seem to be inversely related in initiating cell damage.
w 2qxThat means, large changes of Ca are acutelyi
effective in inducing cell death, e.g., after toxin
application. However, the same effect may be ob-
tained by chronic exposure to a small but permanent
Ca2q overload.
Under several pathological conditions, a reduced
response of intracellular Ca2q to stimuli is observed.
This leads to a functional defect of the cells. Thereby,
w 2qxbasal Ca is only sometimes affected, whereasi
Ca2q mobilization upon stimulation is clearly sup-
pressed. The origin of this phenomenon is unclear. It
may be that a state of decreased response follows a
phase of increased Ca2q responsiveness. Such de-
creased Ca2q responses also might be due to dis-
turbed signalling pathways. In this context, a de-
creased activation of G-proteins, decreased levels of
IP or lower responsiveness of intracellular Ca2q3
channels might be potential pathological mechanisms.
These alterations can also be caused by a reduced
refilling of intracellular stores, a more efficient Ca2q
extrusion, or both. Expression of Ca2q sequestering
systems may be downregulated or their activity may
be changed by phosphorylationrdephosphorylation
processes. Furthermore, an upregulation of a Ca2q
extrusion system, such as the NaqrCa2q exchanger,
has been reported.
Although cells with decreased Ca2q availability
demonstrate an impaired functionality, this does not
necessarily mean that cell viability in general is
impaired. The increased or reduced cellular function-
ality may precede the loss of cellular integrity, for a
more or less extended time period, which is part of a
chronic disease.
It should be noted that all the changes described
above for the cellular level also have implications for
the function of whole organs and even the life of a
patient. The extent of impairment depends thereby on
the availability and effectivity of repair mechanisms
as well as the duration of the alteration. In particular,
the disturbance in cellular Ca2q might not lead to the
death of the afflicted cell in chronic diseases, but the
failure of body function might ultimately be caused
by secondary effects on other vital organ systems.
5. Epilogue
Thus, in acute and chronic diseases, severe distur-
bances in Ca2q handling by the affected cells are
observed. This contribution attempted to deduce some
basic principles to explain some of these alterations.
In order to do so, the complex in vivo situation had to
be simplified considerably. Nevertheless, the authors
hope that their approach will stimulate studies on this
important subject that lead to a deeper insight into the
cellular and molecular basis of disease processes.
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